A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

Starting soon · Phase 2/Phase 3

Conditions studied: Castration-resistant Prostate Cancer

In brief

This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.

Key facts

Study ID

NCT07641855

Run by

Sichuan Baili Pharmaceutical Co., Ltd.

People needed

180

Starts

2026-09-01

Expected to finish

2028-12-01

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntarily join this study and sign the informed consent form;
• Age ≥ 18 years;
• Expected survival time ≥ 3 months;
• Unresectable metastatic castration-resistant prostate cancer;
• Meet the definition of mCRPC according to PCWG3 criteria;
• Agree to provide archived tumor tissue specimens from primary or metastatic lesions within 3 years or fresh tissue samples;
• Meet the evaluable lesion requirement defined by any one of the following assessment criteria;
• ECOG performance status score of 0 or 1;
• Toxicities from prior anti-tumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
• No severe cardiac dysfunction, with left ventricular ejection fraction ≥ 50%;
• Organ function levels must meet the required criteria;
• Urine protein ≤ 1+ or < 1000 mg/24h;
• All enrolled patients must use adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment.

You may not qualify if…

• Patients with metastatic castration-resistant prostate cancer who are suitable for radical local therapy;
• Patients with non-prostatic acinar adenocarcinoma confirmed by histopathology or cytology, among others;
• Patients who have previously received antibody-drug conjugates using topoisomerase I inhibitors as the toxin, among others;
• Use of chemotherapy, targeted therapy, biological therapy, etc., within 4 weeks or 5 half-lives prior to study randomization;
• History of severe heart disease or cerebrovascular disease;
• Long-term systemic corticosteroid therapy with prednisone >10 mg/day ongoing before the first dose, among others;
• Active autoimmune diseases and inflammatory diseases;
• Any thrombotic event within 6 months prior to randomization;
• Prolonged QTc interval, complete left bundle branch block, etc.;
• Diagnosis of active malignant tumors within 3 years prior to study randomization;
• Hypertension inadequately controlled by two antihypertensive medications;
• Patients with poorly controlled blood glucose;
• History of ILD requiring steroid therapy, or current ILD, or grade ≥2 radiation pneumonitis;
• Concurrent pulmonary diseases resulting in clinically severe respiratory function impairment;
• Patients with active central nervous system metastases;
• Severe infection occurring within 4 weeks prior to study randomization, etc.;
• Presence of large serous cavity effusion, or serous cavity effusion with symptoms, etc.;
• Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.;
• Severe non-healing wounds, ulcers, or fractures within 4 weeks prior to signing informed consent;
• Trial participants with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;
• Patients with inflammatory bowel disease, history of extensive bowel resection, history of immune-related enteritis, intestinal obstruction, or chronic diarrhea, etc.;
• Patients with a history of allergy to recombinant humanized antibodies or allergy to the investigational drug;
• History of autologous or allogeneic stem cell transplantation;
• Positive for human immunodeficiency virus antibodies, active hepatitis B virus infection, or hepatitis C virus infection;
• History of severe neurological or psychiatric disorders;

Where it is running

• The First Medical Center of Chinese PLA General Hospital — Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) — Shanghai, Shanghai Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.